2017 Press Releases

Webcast ImageWebcast
Corvus Pharmaceuticals Inc at the 2017 Wedbush PacGrow Healthcare Conference (Replay)
08/16/17 at 1:20 p.m. ET
Corvus Pharmaceuticals Inc at the 2017 Wedbush PacGrow Healthcare Conference
Wednesday, August 16, 2017 1:20 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015
DateTitle 
08/11/17Corvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare Conference
BURLINGAME, Calif., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the 2017 Wedbush PacGrow Healthcare Conference in New York City, New York. The presentation is scheduled for Wednesday, August 16, at 1:20pm Eastern Time. A webcast of the presentation will be available live and for 30 d... 
Printer Friendly Version
08/03/17Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
BURLINGAME, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the second quarter ended June 30, 2017, and provided a business update. “We continue to make significant progress in advancing the clinical development of our lead product candidate, CPI-444, and other product candidates in our imm... 
Printer Friendly Version
07/06/17Corvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-Oncology
BURLINGAME, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will host an R&D Day on Tuesday, July 11, 2017, in New York City and provide a live webcast starting at 9:00 a.m. ET.  The event will focus on the adenosine pathway in immuno-oncology and its potential to address the limitations of existing agen... 
Printer Friendly Version
06/05/17Corvus Pharmaceuticals Announces Interim Results Demonstrating Anti-Tumor Activity of CPI-444 in Renal and Lung Cancer Patients Resistant or Refractory to Prior PD-(L)1 Treatment
-- Clinical Data from Company’s Ongoing Phase 1/1b Study in Expansion Cohorts Presented in Oral Presentation at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting – Key Study Results in RCC Patients ... 
Printer Friendly Version
05/15/17Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 in Renal and Lung Cancer at 2017 ASCO Annual Meeting
BURLINGAME, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present an oral abstract presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago, Illinois. The abstract for the presentation will be available on the ASCO website on May 17 at 5:00 ... 
Printer Friendly Version
05/09/17Corvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology Program
BURLINGAME, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company, announced today that it has licensed global rights to an undisclosed novel immuno-oncology program, which includes a lead product candidate, from Monash University. Corvus Pharmaceuticals, which focuses on the development and commercialization of novel immuno-oncology therapies, plans to develop any product candidates that result from the collaboration... 
Printer Friendly Version
05/04/17Corvus Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
BURLINGAME, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the first quarter ended March 31, 2017, and provided a business update. “We are continuing to make significant progress in our Phase 1/1b trial, which is designed to rapidly identify the diseases where our lead product candidate, CP... 
Printer Friendly Version
05/02/17Corvus Pharmaceuticals Expands CPI-444 Clinical Collaboration with Genentech
CPI-444 in Combination with Atezolizumab Will Advance into Phase 1b/2 Study in Patients with Non-Small Cell Lung Cancer who are Resistant/Refractory to Prior Anti-PD(L)-1 Treatment as Part of MORPHEUS, Genentech’s Novel Cancer Immunotherapy Development Platform BURLINGAME, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today ann... 
Printer Friendly Version
04/04/17Corvus Pharmaceuticals Announces Interim Results from Ongoing Phase 1/1b Study Demonstrating Safety and Clinical Activity of Lead Checkpoint Inhibitor CPI-444 in Patients with Advanced Cancers
– Clinical Data Presented in Oral Plenary Session at American Association for Cancer Research (AACR) Annual Meeting 2017 – – Data Supports Expansion of Three Additional Cohorts in Non-small Cell Lung Cancer Treated with Single Agent CPI-444, Renal Cell Cancer and Non-small Cell Lung Cancer Treated with CPI-444 in Combination with Atezolizumab –  – Additional CPI-444 Data and Preclinical Data on Corvus’ Anti-CD73 Monoclonal Antibody to be Presented in Poster Sessions – BURLINGAME, Calif., A... 
Printer Friendly Version
03/20/17Corvus Pharmaceuticals to Present Data That Advances the Understanding of the Adenosine Pathway in Immuno-Oncology, including New Clinical Data on CPI-444 at AACR 2017
Company Has Six Presentations at AACR Highlighting Clinical and Preclinical Data BURLINGAME, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present interim data from its ongoing Phase 1/1b study of CPI-444 as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab) in an oral ple... 
Printer Friendly Version
03/13/17Corvus Pharmaceuticals to Reschedule R&D Day Due to Severe Winter Storm in the New York Tri-State Area
BURLINGAME, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, announced that the company will postpone its R&D Day scheduled for March 14, 2017 due to an anticipated severe winter snowstorm forecasted to hit the New York tri-state area and its impact on the travel schedule and participation of its principal presenters. The comp... 
Printer Friendly Version
03/10/17Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
BURLINGAME, Calif., March 10, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the fourth quarter and year ended December 31, 2016, and provided a business update. “In 2016, Corvus made the successful transition to becoming a public company, initiated clinical investigation of our lead program, CPI-444, and ... 
Printer Friendly Version
03/09/17Corvus Pharmaceuticals to Host R&D Day Highlighting the Role of the Adenosine Pathway in Immuno-Oncology
Company to Provide Opportunity to Participate in the Event via Live and Archived Webcast BURLINGAME, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will host and provide a live webcast for its R&D Day, starting at 9:00 AM ET on March 14, 2017 in New York City.   The event will highlight the... 
Printer Friendly Version
02/27/17Corvus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference 2017
BURLINGAME, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the Cowen and Company 37th Annual Health Care Conference 2017 in Boston, Massachusetts. The presentation is scheduled for Monday, March 6, at 4:00 p.m. Eastern Time. A webcast of the presentation will be available live a... 
Printer Friendly Version
01/10/17Corvus Pharmaceuticals Announces Expansion of Renal Cell Carcinoma Cohort in Ongoing Phase 1/1b Clinical Study of Lead Checkpoint Inhibitor CPI-444
-- Cohort Reached Protocol-Predefined Criteria for Expansion  Based on Responses to Single-Agent Treatment -- BURLINGAME, Calif., Jan. 10, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the protocol-predefined criteria for expansion has been reached for the cohort of patients with renal cell carcinoma treated with single-ag... 
Printer Friendly Version
01/04/17Corvus Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference 2017
BURLINGAME, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the 35th Annual J.P. Morgan Healthcare Conference 2017 in San Francisco. The presentation is scheduled for Thursday, January 12, at 8:00 a.m. Pacific Time. A webcast of the presentation will be available live and for 7 d... 
Printer Friendly Version
01/03/17Corvus Pharmaceuticals Names Ian T. Clark, Former Genentech Chief Executive Officer, to Board of Directors
BURLINGAME, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS) today announced the appointment of Ian T. Clark, former chief executive officer and head of North American Commercial Operations at Genentech, Inc., to its Board of Directors. "Ian is an ideal addition to our Board because of his considerable expertise in guiding the commercialization of novel therapeutics, particularly in oncology,” said Richard A. Miller, an oncologist and co-founder, presiden... 
Printer Friendly Version